The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Dorofeev D.A.

Municipal Clinical Hospital No. 2, Outpatient Department No. 1

Vitkov A.A.

Research Institute of Eye Diseases

Gorobets A.V.

Center of Additional Education;
South Ural State University (SRU) — Institute of Natural and Precise Sciences

Eskova M.V.

Municipal Clinical Hospital No. 2, Outpatient Department No. 1

Efimova K.A.

Municipal Clinical Hospital No. 2, Outpatient Department No. 1

Kanafin E.V.

South Ural State University (SRU) — Institute of Natural and Precise Sciences

Kirilik E.V.

Polyclinic No 1 of the City Clinical Hospital No. 2

Lukyanova K.O.

Municipal Clinical Hospital No. 2, Outpatient Department No. 1

Effectiveness and safety of a hypotensive preservative-free drug in long-term therapy of glaucoma

Authors:

Dorofeev D.A., Vitkov A.A., Gorobets A.V., Eskova M.V., Efimova K.A., Kanafin E.V., Kirilik E.V., Lukyanova K.O.

More about the authors

Journal: Russian Annals of Ophthalmology. 2022;138(5): 66‑72

DOI: 10.17116/oftalma202213805166

Read: 2384 times

Download PDF (RU)
Contact the author
Table of contents

EFFECTIVENESS AND SAFETY OF A HYPOTENSIVE PRESERVATIVE-FREE DRUG IN LONG-TERM THERAPY OF GLAUCOMA
EFFECTIVENESS AND SAFETY OF A HYPOTENSIVE PRESERVATIVE-FREE DRUG IN LONG-TERM THERAPY OF GLAUCOMA

To cite this article:

Dorofeev DA, Vitkov AA, Gorobets AV, et al. . Effectiveness and safety of a hypotensive preservative-free drug in long-term therapy of glaucoma. Russian Annals of Ophthalmology. 2022;138(5):66‑72. (In Russ.)
https://doi.org/10.17116/oftalma202213805166

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Microbiota of the ocular surface in children with myopia. Russian Annals of Ophthalmology. 2025;(3):5-12
The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(4):49-59
Electrophysiological methods in the diagnosis and moni­toring of glaucoma. Russian Annals of Ophthalmology. 2025;(4):102-109
The effect of initial conservative hypo­tensive therapy on the outcomes of sele­ctive laser trabeculoplasty in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(5):16-22
Modern devi­ces for microinvasive glaucoma surgery. Russian Annals of Ophthalmology. 2025;(5):101-108
Comparative evaluation of tono­metry methods in kera­toconus. Russian Annals of Ophthalmology. 2025;(6):7-13
Neuroprotective therapy in adva­nced primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(6):75-80
Abstract:

PURPOSE

To investigate the condition of the ocular surface and the effectiveness of Taflotan for long-term therapy in patients with newly diagnosed primary open-angle glaucoma in real clinical practice.

MATERIAL AND METHODS

This publication presents data form a retrospective observational study that analyzed newly diagnosed glaucoma patients that have been using 1 drop/day of Taflotan in the evening for 12 months. All patients were examined at baseline, and after 1 month and 12 months of treatment, recording intraocular pressure (IOP), retinal photosensitivity indicators (MD, PSD), thickness of the retinal nerve fiber layer (RNFL), and assessing the condition of the ocular surface by Schirmer test, tear breakup time (TBUT), ocular surface disease index (OSDI) questionnaire, as well as measurement of the lacrimal meniscus height and corneal staining with lissamine green.

RESULTS

IOP effectively decreased in all patients using Taflotan, reaching the target pressure by 1 month after therapy initiation. IOP decreased from 25±4 mm Hg at baseline to 17±3mm Hg after 1 month with further decrease down to 16±3 mm Hg after 12 months of therapy. Retinal photosensitivity (MD and PSD) and RNFL thickness did not differ from baseline, and correlated to glaucoma stage. The indicators of the condition of the ocular surface had no significant differences between the baseline, 1-month and 12-month time points.

CONCLUSION

Taflotan effectively decreases IOP in newly diagnosed glaucoma patients, maintains stable automated perimetry indices and RNFL thickness, and does not affect the ocular surface throughout 12 months of therapy.

Keywords:

Taflotan
glaucoma
intraocular pressure
ocular surface

Authors:

Dorofeev D.A.

Municipal Clinical Hospital No. 2, Outpatient Department No. 1

Vitkov A.A.

Research Institute of Eye Diseases

Gorobets A.V.

Center of Additional Education;
South Ural State University (SRU) — Institute of Natural and Precise Sciences

Eskova M.V.

Municipal Clinical Hospital No. 2, Outpatient Department No. 1

Efimova K.A.

Municipal Clinical Hospital No. 2, Outpatient Department No. 1

Kanafin E.V.

South Ural State University (SRU) — Institute of Natural and Precise Sciences

Kirilik E.V.

Polyclinic No 1 of the City Clinical Hospital No. 2

Lukyanova K.O.

Municipal Clinical Hospital No. 2, Outpatient Department No. 1

Received:

17.08.2022

Accepted:

08.09.2022

Close metadata

References:

  1. Bourne RRA, Jonas JB, Bron AM, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol. 2018;102(5): 575-585.  https://doi.org/10.1136/BJOPHTHALMOL-2017-311258
  2. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975):1295-1304. https://doi.org/10.1016/S0140-6736(14)62111-5
  3. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279. https://doi.org/10.1001/archopht.120.10.1268
  4. Kiyota N, Shiga Y, Omodaka K, Nakazawa T. The relationship between choroidal blood flow and glaucoma progression in a Japanese study population. Jpn J Ophthalmol. 2022;66(5):425-433.  https://doi.org/10.1007/s10384-022-00929-w
  5. Kurysheva NI. The role of retinal microcirculation disorders in the progression of glaucomatous optic neuropathy. Vestnik oftal’mologii. 2020;136(4):57-65. (In Russ.). https://doi.org/10.17116/oftalma202013604157
  6. Shukla AG, De Moraes CG, Cioffi GA, et al. The Relationship Between Intraocular Pressure and Rates of Central Versus Peripheral Visual Field Progression. J Glaucoma. 2020;29(6):435-440.  https://doi.org/10.1097/IJG.0000000000001494
  7. Han YS, Ha A, Kim YK, Jeoung JW, Park KH. Normal-tension Glaucoma Management: A Survey of Glaucoma Sub-specialists in Korea. Korean J Ophthalmol. 2020;34(6):425-431.  https://doi.org/10.3341/KJO.2020.0061
  8. Mansouri K, Tanna AP, De Moraes CG, Camp AS, Weinreb RN. Review of the measurement and management of 24-hour intraocular pressure in patients with glaucoma. Surv Ophthalmol. 2020;65(2):171-186.  https://doi.org/10.1016/J.SURVOPHTHAL.2019.09.004
  9. Baudouin C, Denoyer A, Desbenoit N, Hamm G, Grise A. In Vitro and in Vivo Experimental Studies on Trabecular Meshwork Degeneration Induced by Benzalkonium Chloride (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc. 2012;110:40. 
  10. Chamard C, Larrieu S, Baudouin C, Bron A, Villain M, Daien V. Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008—2016. Acta Ophthalmologica. 2020;98(7):876-881.  https://doi.org/10.1111/aos.14410
  11. Pflugfelder SC, de Paiva CS. The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research. Ophthalmology. 2017;124(11): 4-13.  https://doi.org/10.1016/j.ophtha.2017.07.010
  12. Dorofeev DA, Brezhnev AY, Gazizova IR, et al. Prerequisites to use preservative-free drugs in medication therapy of glaucoma. Oftalmologiya. 2021; 18(3):532-538.  https://doi.org/10.18008/1816-5095-2021-3-532-538
  13. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with laucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618-621.  https://doi.org/10.1097/ICO.0b013e3181c325b2
  14. Prum BE, Rosenberg LF, Gedde SJ, et al. Primary Open-Angle Glaucoma. Ophthalmology. 2016;123(1):41-111.  https://doi.org/10.1016/j.ophtha.2015.10.053
  15. Petrov SYu, Safonova DM. Ophthalmic preservatives: from benzalkonium chloride to polyquaternium. Literature review. RMZh. Klinicheskaya oftal’mlogiya. 2014;(2):97. (In Russ.).
  16. Sekine Y, Shimada M, Satake S, Okubo M, Hisaka A, Hara T, Honjo M, Aihara M. Pharmacokinetic analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes. J Ocul Pharmacol Ther. 2018;34(3):280-286.  https://doi.org/10.1089/jop.2017.0091
  17. Tong L, Matsuura E, Takahashi M, Nagano T, Kawazu K. Effects of Anti-Glaucoma Prostaglandin Ophthalmic Solutions on Cultured Human Corneal Epithelial Cells. Curr Eye Res. 2019;44(8):856-862.  https://doi.org/10.1080/02713683.2019.1597127
  18. Kim JM, Sung KR, Lee JW, Kyung H, Rho S, Kim CY. Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial. Int J Ophthalmol. 2021;14(10):1539. https://doi.org/10.18240/IJO.2021.10.10
  19. Abysheva LD, Avdeyev RV, Aleksandrov AS, et al. Influence of local hypotensive glaucoma therapy on the development and progression of dry eye syndrome. RMZh. Klinicheskaya oftal’mologiya. 2017;17(2):74-82. (In Russ.). https://doi.org/10.21689/2311-7729-2017-17-2-74-82
  20. Dorofeev DA, Tur EV, Vizgalova LO, Tryapitsin ID, Ciganov AZ. The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results). The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(6):52-59. (In Russ.). https://doi.org/10.17116/oftalma201913506152
  21. Dorofeev DA, Kryzhanovskaya AV, Ciganov AZ. Effectiveness of antihypertensive conservative-free therapy with fixed combination of bimatoprost and timolol (intermediate results). The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2020;136(2):73-80. (In Russ.). https://doi.org/10.17116/oftalma202013602173
  22. Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of glaucoma medication adherence over four years of follow-up. Ophthalmology. 2015;122(10):2010-2021. https://doi.org/10.1016/j.ophtha.2015.06.039
  23. Lovpache DzhN, Dorofeev DA. Pharmacoeconomic expediency of the use of preservative-free therapy in the treatment of primary open-angle glaucoma in patients with the dry eyesyndrome (intermediate results). RMJ. Clinical Ophthalmology = RMZh. Klinicheskaya oftal’mologiya. 2017;17(4):195-200. (In Russ.). https://doi.org/10.21689/2311-7729-2017-17-4-195-200
  24. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmologica. 2010;88(3):329-336.  https://doi.org/10.1111/j.1755-3768.2010.01907.x
  25. Clinical guidelines. Primary open-angle glaucoma. 2017. Approved by the Ministry of Health of the Russian Federation. (In Russ.).
  26. Clinical guidelines. Primary open-angle glaucoma. 2020 (02.16.21). Approved by the Ministry of Health of the Russian Federation. (In Russ.).
  27. ICD-10 — International Classification of Diseases 10th Revision. (In Russ.). https://mkb-10.com/
  28. Erb C, Lanzl I, Seidova SF, Kimmich F. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Adv Ther. 2011;28(7):575-585.  https://doi.org/10.1007/s12325-011-0038-9
  29. Hwang YH. Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma. Clin Ophthalmol. 2014;8(1):71-72.  https://doi.org/10.2147/OPTH.S57089
  30. Boyko EV, Simakova IL, Yakushev DYu, Ignat’ev SA, Alekseev IB, Mel’nikova NV, Alyab’ev MV, Maltsev DS. Dry eye syndrome in patients with primary open-angle glaucoma. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2015;131(3):22-26. (In Russ.). https://doi.org/10.17116/oftalma2015131322-26
  31. Fogagnolo P, Dipinto A, Vanzulli E, Maggiolo E, De Cilla’ S, Autelitano A, Rossetti L. A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients. Adv Ther. 2015;32(4):356-369. Epub 2015 Apr 19.  https://doi.org/10.1007/s12325-015-0205-5
  32. Neroyev VV, Zolotarev AV, Karlova EV, Kiseleva OA, Shishkin MM, Germanova VN. Influence of treatment adherence on the progression of primary open-angle glaucoma in clinical setting. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(6):42-51. (In Russ.). https://doi.org/10.17116/oftalma201913506142
  33. Kurysheva N.I. Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination. Taiwan J Ophthalmol. 2019;9(2):93-99.  https://doi.org/10.4103/tjo.tjo_108_17
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.